Abbott Laboratories (ABT) Competitors

$82.58 -1.74 (-2.06%)

Closing price 03:59 PM Eastern

Extended Trading

$82.82 +0.24 (+0.29%)

As of 06:11 PM Eastern

ABT vs. DXCM, ISRG, TSLA, ABBV, and BSX

Should you be buying Abbott Laboratories stock or one of its competitors? The main competitors of Abbott Laboratories include DexCom (DXCM), Intuitive Surgical (ISRG), Tesla (TSLA), AbbVie (ABBV), and Boston Scientific (BSX).

How does Abbott Laboratories compare to DexCom?

Abbott Laboratories (NYSE:ABT) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

DexCom has a net margin of 19.31% compared to Abbott Laboratories' net margin of 13.90%. DexCom's return on equity of 33.33% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	13.90%	17.62%	10.01%
DexCom	19.31%	33.33%	13.19%

75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Abbott Laboratories had 10 more articles in the media than DexCom. MarketBeat recorded 32 mentions for Abbott Laboratories and 22 mentions for DexCom. DexCom's average media sentiment score of 1.19 beat Abbott Laboratories' score of 1.04 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	20 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
DexCom	14 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Abbott Laboratories has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.

Abbott Laboratories presently has a consensus target price of $119.43, suggesting a potential upside of 44.63%. DexCom has a consensus target price of $83.50, suggesting a potential upside of 40.74%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, equities analysts plainly believe Abbott Laboratories is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	3.24	$6.52B	$3.57	23.13
DexCom	$4.66B	4.91	$836.30M	$2.34	25.35

Summary

DexCom beats Abbott Laboratories on 8 of the 15 factors compared between the two stocks.

How does Abbott Laboratories compare to Intuitive Surgical?

Intuitive Surgical (NASDAQ:ISRG) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

83.6% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Abbott Laboratories has higher revenue and earnings than Intuitive Surgical. Abbott Laboratories is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$10.58B	14.06	$2.86B	$8.25	50.92
Abbott Laboratories	$44.33B	3.24	$6.52B	$3.57	23.13

Intuitive Surgical presently has a consensus price target of $581.91, suggesting a potential upside of 38.53%. Abbott Laboratories has a consensus price target of $119.43, suggesting a potential upside of 44.63%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Abbott Laboratories is more favorable than Intuitive Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	1 Sell rating(s)	7 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.65
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

Intuitive Surgical has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.

In the previous week, Intuitive Surgical had 5 more articles in the media than Abbott Laboratories. MarketBeat recorded 37 mentions for Intuitive Surgical and 32 mentions for Abbott Laboratories. Intuitive Surgical's average media sentiment score of 1.51 beat Abbott Laboratories' score of 1.04 indicating that Intuitive Surgical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intuitive Surgical	31 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Very Positive
Abbott Laboratories	20 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Intuitive Surgical has a net margin of 28.15% compared to Abbott Laboratories' net margin of 13.90%. Abbott Laboratories' return on equity of 17.62% beat Intuitive Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	28.15%	15.98%	14.07%
Abbott Laboratories	13.90%	17.62%	10.01%

Summary

Intuitive Surgical beats Abbott Laboratories on 10 of the 17 factors compared between the two stocks.

How does Abbott Laboratories compare to Tesla?

Tesla (NASDAQ:TSLA) and Abbott Laboratories (NYSE:ABT) are related large-cap companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Tesla has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.

66.2% of Tesla shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 19.9% of Tesla shares are owned by insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Tesla had 193 more articles in the media than Abbott Laboratories. MarketBeat recorded 225 mentions for Tesla and 32 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 1.04 beat Tesla's score of 0.85 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tesla	125 Very Positive mention(s)	35 Positive mention(s)	37 Neutral mention(s)	18 Negative mention(s)	5 Very Negative mention(s)	Positive
Abbott Laboratories	20 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Abbott Laboratories has a net margin of 13.90% compared to Tesla's net margin of 3.95%. Abbott Laboratories' return on equity of 17.62% beat Tesla's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tesla	3.95%	4.89%	2.93%
Abbott Laboratories	13.90%	17.62%	10.01%

Tesla currently has a consensus price target of $398.42, suggesting a potential downside of 10.45%. Abbott Laboratories has a consensus price target of $119.43, suggesting a potential upside of 44.63%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Abbott Laboratories is more favorable than Tesla.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tesla	5 Sell rating(s)	17 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.34
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

Abbott Laboratories has lower revenue, but higher earnings than Tesla. Abbott Laboratories is trading at a lower price-to-earnings ratio than Tesla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tesla	$94.83B	17.62	$3.79B	$1.09	408.18
Abbott Laboratories	$44.33B	3.24	$6.52B	$3.57	23.13

Summary

Abbott Laboratories beats Tesla on 10 of the 16 factors compared between the two stocks.

How does Abbott Laboratories compare to AbbVie?

Abbott Laboratories (NYSE:ABT) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Abbott Laboratories has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500.

In the previous week, AbbVie had 29 more articles in the media than Abbott Laboratories. MarketBeat recorded 61 mentions for AbbVie and 32 mentions for Abbott Laboratories. AbbVie's average media sentiment score of 1.16 beat Abbott Laboratories' score of 1.04 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	20 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
AbbVie	42 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Abbott Laboratories has a net margin of 13.90% compared to AbbVie's net margin of 5.79%. Abbott Laboratories' return on equity of 17.62% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	13.90%	17.62%	10.01%
AbbVie	5.79%	-911.57%	13.43%

75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Abbott Laboratories currently has a consensus price target of $119.43, indicating a potential upside of 44.63%. AbbVie has a consensus price target of $252.90, indicating a potential upside of 24.70%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, research analysts clearly believe Abbott Laboratories is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

Abbott Laboratories has higher earnings, but lower revenue than AbbVie. Abbott Laboratories is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	3.24	$6.52B	$3.57	23.13
AbbVie	$62.82B	5.71	$4.23B	$2.03	99.91

Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 3.1%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.4%. Abbott Laboratories pays out 70.6% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories has increased its dividend for 54 consecutive years and AbbVie has increased its dividend for 53 consecutive years.

Summary

Abbott Laboratories beats AbbVie on 12 of the 20 factors compared between the two stocks.

How does Abbott Laboratories compare to Boston Scientific?

Abbott Laboratories (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

In the previous week, Abbott Laboratories had 7 more articles in the media than Boston Scientific. MarketBeat recorded 32 mentions for Abbott Laboratories and 25 mentions for Boston Scientific. Abbott Laboratories' average media sentiment score of 1.04 beat Boston Scientific's score of 0.66 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	20 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Boston Scientific	13 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Abbott Laboratories has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.

Abbott Laboratories has higher revenue and earnings than Boston Scientific. Boston Scientific is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	3.24	$6.52B	$3.57	23.13
Boston Scientific	$20.61B	3.84	$2.90B	$2.39	22.31

Boston Scientific has a net margin of 17.29% compared to Abbott Laboratories' net margin of 13.90%. Boston Scientific's return on equity of 19.17% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	13.90%	17.62%	10.01%
Boston Scientific	17.29%	19.17%	10.77%

Abbott Laboratories currently has a consensus price target of $119.43, suggesting a potential upside of 44.63%. Boston Scientific has a consensus price target of $93.91, suggesting a potential upside of 76.10%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Boston Scientific is more favorable than Abbott Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Boston Scientific	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.92

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 89.1% of Boston Scientific shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by insiders. Comparatively, 0.3% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Abbott Laboratories beats Boston Scientific on 9 of the 17 factors compared between the two stocks.

Get Abbott Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABT vs. The Competition

Export

Metric	Abbott Laboratories	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$143.84B	$7.85B	$6.18B	$22.92B
Dividend Yield	2.99%	2.50%	2.78%	4.02%
P/E Ratio	23.13	16.79	20.66	28.92
Price / Sales	3.24	7.91	528.16	24.52
Price / Cash	12.06	17.15	27.81	19.21
Price / Book	2.72	3.51	9.77	4.65
Net Income	$6.52B	$223.05M	$3.54B	$1.07B
7 Day Performance	N/A	N/A	N/A	-1.20%
1 Month Performance	-17.55%	38.64%	6.25%	3.95%
1 Year Performance	-38.14%	4.05%	41.74%	28.96%

Abbott Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABT Abbott Laboratories	4.9602 of 5 stars	$82.58 -2.1%	$119.43 +44.6%	-36.9%	$143.84B	$44.33B	23.13	115,000	Positive News Analyst Revision
DXCM DexCom	4.7294 of 5 stars	$60.04 -2.1%	$83.50 +39.1%	-28.4%	$23.67B	$4.66B	25.66	11,000	Analyst Downgrade
ISRG Intuitive Surgical	4.2734 of 5 stars	$452.35 -1.2%	$581.91 +28.6%	-16.1%	$162.13B	$10.06B	54.83	17,021	Positive News Analyst Revision
TSLA Tesla	2.6686 of 5 stars	$392.38 +0.4%	$398.42 +1.5%	+43.7%	$1.47T	$94.83B	359.98	134,785	Trending News Analyst Revision
ABBV AbbVie	4.9387 of 5 stars	$208.00 +0.7%	$252.90 +21.6%	+9.2%	$365.30B	$62.82B	102.46	57,000	Positive News Analyst Upgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ABT) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abbott Laboratories (ABT) Competitors

ABT vs. DXCM, ISRG, TSLA, ABBV, and BSX

How does Abbott Laboratories compare to DexCom?

Summary

How does Abbott Laboratories compare to Intuitive Surgical?

Summary

How does Abbott Laboratories compare to Tesla?

Summary

How does Abbott Laboratories compare to AbbVie?

Summary

How does Abbott Laboratories compare to Boston Scientific?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABT vs. The Competition

Abbott Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abbott Laboratories (ABT) Competitors

ABT vs. DXCM, ISRG, TSLA, ABBV, and BSX

How does Abbott Laboratories compare to DexCom?

Is ABT or DXCM more profitable?

Do institutionals & insiders hold more shares of ABT or DXCM?

Does the media prefer ABT or DXCM?

Which has more volatility & risk, ABT or DXCM?

Do analysts recommend ABT or DXCM?

Which has better valuation and earnings, ABT or DXCM?

Summary

How does Abbott Laboratories compare to Intuitive Surgical?

Do insiders and institutionals hold more shares of ISRG or ABT?

Which has preferable valuation & earnings, ISRG or ABT?

Do analysts recommend ISRG or ABT?

Which has more risk & volatility, ISRG or ABT?

Does the media prefer ISRG or ABT?

Is ISRG or ABT more profitable?

Summary

How does Abbott Laboratories compare to Tesla?

Which has more risk and volatility, TSLA or ABT?

Do institutionals and insiders hold more shares of TSLA or ABT?

Does the media favor TSLA or ABT?

Is TSLA or ABT more profitable?

Do analysts recommend TSLA or ABT?

Which has higher earnings & valuation, TSLA or ABT?

Summary

How does Abbott Laboratories compare to AbbVie?

Which has more risk & volatility, ABT or ABBV?

Does the media refer more to ABT or ABBV?

Is ABT or ABBV more profitable?

Do insiders and institutionals have more ownership in ABT or ABBV?

Do analysts rate ABT or ABBV?

Which has stronger valuation and earnings, ABT or ABBV?

Is ABT or ABBV a better dividend stock?

Summary

How does Abbott Laboratories compare to Boston Scientific?

Does the media refer more to ABT or BSX?

Which has more risk and volatility, ABT or BSX?

Which has preferable valuation & earnings, ABT or BSX?

Is ABT or BSX more profitable?

Do analysts recommend ABT or BSX?

Do insiders & institutionals have more ownership in ABT or BSX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABT vs. The Competition

Abbott Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools